Skip to main content
Journal cover image

Dendritic cell vaccines targeting survivin in head and neck cancer.

Publication ,  Other
Lee, WT
Published in: Immunotherapy
November 2013

Evaluation of: Turksma AW, Bontkes HJ, Ruizendaal JJ et al. Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J. Transl. Med. 11, 152-165 (2013). Survivin has been identified to be an inhibitor of apoptosis and is highly expressed in many cancers. A number of strategies have targeted survivin as a novel cancer therapy approach. The evaluated paper makes a number of observations regarding the presence of survivin-specific T cells, as well as attempts for in vitro expansion. The research team has shown that survivin-specific T cells can be measured ex vivo in the peripheral blood of patients with head and neck squamous cell carcinoma by tetramer analysis and from the tumor-draining lymph node of a patient with locally advanced breast cancer by ELIspot analysis. Furthermore, dendritic cells electroporated with survivin and cytokine (i.e., IL-12 and IL-21) mRNA can be used to generate survivin-specific T cells in vitro. However, the enriched or cloned survivin-specific T cells isolated from patients or obtained by in vitro induction could not be maintained for prolonged periods of time. The study team proposed that one explanation for this is fracticide, as activated T cells were shown to express survivin. The evaluated paper therefore concluded that strategies that rely on expansion and adoptive transfer of survivin-specific T cells would not be possible.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Immunotherapy

DOI

EISSN

1750-7448

Publication Date

November 2013

Volume

5

Issue

11

Start / End Page

1169 / 1171

Location

England

Related Subject Headings

  • T-Lymphocytes
  • Inhibitor of Apoptosis Proteins
  • Humans
  • Head and Neck Neoplasms
  • Dendritic Cells
  • Carcinoma
  • Cancer Vaccines
  • 3211 Oncology and carcinogenesis
  • 3204 Immunology
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lee, W. T. (2013). Dendritic cell vaccines targeting survivin in head and neck cancer. Immunotherapy. England. https://doi.org/10.2217/imt.13.120
Lee, Walter T. “Dendritic cell vaccines targeting survivin in head and neck cancer.Immunotherapy, November 2013. https://doi.org/10.2217/imt.13.120.
Lee WT. Dendritic cell vaccines targeting survivin in head and neck cancer. Vol. 5, Immunotherapy. 2013. p. 1169–71.
Lee, Walter T. “Dendritic cell vaccines targeting survivin in head and neck cancer.Immunotherapy, vol. 5, no. 11, Nov. 2013, pp. 1169–71. Pubmed, doi:10.2217/imt.13.120.
Lee WT. Dendritic cell vaccines targeting survivin in head and neck cancer. Immunotherapy. 2013. p. 1169–1171.
Journal cover image

Published In

Immunotherapy

DOI

EISSN

1750-7448

Publication Date

November 2013

Volume

5

Issue

11

Start / End Page

1169 / 1171

Location

England

Related Subject Headings

  • T-Lymphocytes
  • Inhibitor of Apoptosis Proteins
  • Humans
  • Head and Neck Neoplasms
  • Dendritic Cells
  • Carcinoma
  • Cancer Vaccines
  • 3211 Oncology and carcinogenesis
  • 3204 Immunology
  • 1115 Pharmacology and Pharmaceutical Sciences